Comparing Cost of Revenue Efficiency: Vertex Pharmaceuticals Incorporated vs Jazz Pharmaceuticals plc

Vertex vs. Jazz: A Decade of Cost Efficiency

__timestampJazz Pharmaceuticals plcVertex Pharmaceuticals Incorporated
Wednesday, January 1, 201411741800060987000
Thursday, January 1, 2015102526000125542000
Friday, January 1, 2016105386000210460000
Sunday, January 1, 2017110188000275119000
Monday, January 1, 2018121544000409539000
Tuesday, January 1, 2019127930000547758000
Wednesday, January 1, 2020148917000736300000
Friday, January 1, 2021440760000904200000
Saturday, January 1, 20225405170001080300000
Sunday, January 1, 20234355770001262200000
Monday, January 1, 20241530500000
Loading chart...

In pursuit of knowledge

A Decade of Cost Efficiency: Vertex vs. Jazz Pharmaceuticals

In the competitive landscape of pharmaceuticals, cost efficiency is a critical metric. Over the past decade, Vertex Pharmaceuticals Incorporated and Jazz Pharmaceuticals plc have demonstrated contrasting trajectories in their cost of revenue. From 2014 to 2023, Vertex Pharmaceuticals has shown a remarkable increase in cost efficiency, with their cost of revenue growing by over 1,900%, from approximately $61 million to $1.26 billion. In contrast, Jazz Pharmaceuticals experienced a more modest growth of around 270%, from $117 million to $436 million.

Key Insights

Vertex's aggressive investment in research and development has paid off, allowing them to scale their operations significantly. Meanwhile, Jazz Pharmaceuticals has maintained steady growth, focusing on niche markets. This comparison highlights the diverse strategies within the pharmaceutical industry, where both companies have successfully navigated their paths to profitability.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025